This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Formulations

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Two varieties exist:

  • monophasic / fixed pill
  • multiphasic / varying dose pill

The pattern of usage of the fixed pill depends on the exact preparation. In the most common regimen, pills are first taken on day 5 of a cycle and continued for 21 days. The tablets then either are discontinued for 7 days, or a placebo is taken for 7 days, during which time, withdrawal bleeding may sometimes occur. It is recommended that the pill is taken at the same time each day - usually bedtime - and if omitted, taken the next morning. The patient should be warned that ovulation may not be inhibited in the first cycle of treatment.

Multiphasic preparations contain tablets with varying amounts of oestrogen and progesterone. They aim to simulate a more natural hormonal pattern. The oestrogen content increases from 30 mcg ethinyloestradiol in the first six days to 40 mcg for the next five days, then back to 30 mcg for ten days. The progestogen - levonorgestrel - is increased from 50 mcg to 75 mg to 100 mcg in three stages. It was hoped that variable dose pills would be less likely to cause thromboembolism, but this is yet to be established.


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.